What is the recommended method for switching fluvoxamine from immediate‑release (IR) to extended‑release (ER) formulation, and vice versa?

Switching Between Fluvoxamine IR and ER Formulations

When switching from fluvoxamine immediate-release (IR) to extended-release (ER), or vice versa, use a direct 1:1 dose conversion and make the switch the next day without tapering or overlap. 1

Switching Strategy

IR to ER Conversion

• Calculate the total daily IR dose (e.g., if taking 100 mg twice daily = 200 mg/day total)
• Switch directly to the same total daily dose of ER the following day (e.g., 200 mg ER once daily at bedtime)
• No tapering or washout period is required between formulations
• Administer ER formulation as a single daily dose at bedtime 1

ER to IR Conversion

• Calculate the total daily ER dose (e.g., 200 mg ER once daily)
• Switch to the same total daily dose of IR divided into appropriate dosing intervals
• For doses >100 mg/day, divide into two doses with the larger dose at bedtime 1
• For doses ≤100 mg/day, may give as single bedtime dose 1

Dosing Considerations After Switching

IR Formulation Specifics

• At low doses of IR fluvoxamine, twice-daily dosing may be required due to shorter elimination half-life 2
• When total daily dose exceeds 100 mg, divide into two unequal doses with the larger dose at bedtime 1
• Dose range: 100-300 mg/day for adults 1

ER Formulation Specifics

• ER formulation provides 38% lower maximum plasma concentration and 16% lower bioavailability compared to IR, but maintains therapeutic efficacy 3
• ER allows more rapid titration at treatment initiation (can start at 100 mg) with comparable tolerability to IR 3
• ER provides less daily fluctuation in plasma levels compared to IR 4
• Once-daily dosing at bedtime is standard 1

Critical Safety Considerations

Monitor for Discontinuation Syndrome

Fluvoxamine is associated with discontinuation syndrome characterized by dizziness, fatigue, nausea, sensory disturbances, anxiety, and agitation 2. While switching formulations at equivalent doses should minimize this risk, monitor patients closely during the first 1-2 weeks after switching.

Drug Interactions Remain Unchanged

Fluvoxamine has extensive CYP450 interactions (CYP1A2, CYP2C19, CYP2C9, CYP3A4, CYP2D6) regardless of formulation 2. The switch does not alter interaction risk—continue monitoring for interactions with:

• Alprazolam and triazolam (reduce doses by 50%) 5
• Other serotonergic agents (risk of serotonin syndrome) 2
• Drugs metabolized by affected CYP enzymes

Titration After Switching

• No dose adjustment is typically needed when switching at equivalent doses
• If adjusting dose after switching, increase in 50 mg increments every 4-7 days for IR 1
• For ER, similar titration intervals apply but with the convenience of once-daily dosing 3

Common Pitfalls to Avoid

1. Do not taper when switching formulations at equivalent doses—this is a formulation change, not discontinuation
2. Do not overlap formulations—this would result in overdosing
3. Do not assume ER requires lower doses—despite lower bioavailability, therapeutic equivalence is maintained at the same total daily dose 3, 4
4. Do not forget to adjust timing—ER is once-daily at bedtime, while IR >100 mg/day requires divided dosing 1

The pharmacokinetic differences between formulations (lower peak concentrations with ER) are offset by the extended-release mechanism, resulting in comparable clinical efficacy and safety profiles 4, 6.